ArticleCureus2026
Breakthrough Varicella During Chemotherapy in Two Vaccinated Children With Acute Leukemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough varicella (BTV), defined as varicella occurring more than 42 days after vaccination, is typically milder than primary varicella infection. However, its clinical course in immunocompromised children remains incompletely characterized. We report two pediatric patients undergoing chemotherapy for acute leukemia who developed BTV despite prior two-dose varicella vaccination. Both patients initially presented with atypical and sparse skin eruptions, which delayed diagnosis. During chemotherapy of profound immunosuppression, the rashes rapidly progressed, accompanied by fever and neutropenia. Rapid antigen testing confirmed varicella-zoster virus infection, and early treatment with intravenous acyclovir resulted in clinical improvement without visceral complications or nosocomial transmission. These cases highlight that BTV in immunocompromised hosts might present atypically yet deteriorate quickly. Prompt recognition and early antiviral therapy are essential to prevent severe outcomes. Clinicians should consider varicella even when only a few non-vesicular lesions are observed in vaccinated children receiving chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.